Navigation Links
Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
Date:5/19/2009

ifferentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase signaling cascades can lead to cancer and aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors AKT and mTOR is also known to promote tumor cell survival, proliferation, and growth. Notably, dysregulation of PI3K signaling is thought to contribute to resistance to a variety of anticancer therapies. Thus, PI3K is considered a high value target in treating cancer.

About Semafore Pharmaceuticals, Inc.

Semafore is a clinical stage drug discovery and development company focused on small molecule modulators of the PI3 kinase and PTEN cell signaling pathway, a promising target pathway for multiple disorders, including the company's focus - cancer. Semafore is a leader in the development of PI3K inhibitors and one of the first biopharmaceutical companies to focus on both PI3K and PTEN inhibitors. The Company has successfully discovered and is developing a portfolio of drug candidates addressing these targets. Semafore is also leveraging its experience in the PI3K arena to identify and design inhibitors that block multiple pathways. For more information see the company's web site at www.SemaforePharma.com.


'/>"/>
SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Unique Cardiovascular Treatment Readied for Global Market: Proprietary Paccocath(R) Technology is the Only Drug Eluting Balloon with Clinical Data
2. U.S. Naval Medical Research Center Proposed RESUS Clinical Trial in Trauma Patients Remains on FDA Hold
3. Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
4. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
5. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
11. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 1 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... obesity, today announced that the U.S. Food and Drug ... Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its ... is based on a substantial body of evidence gathered ...
... , IRVINE, Calif. , June 1 Cardiogenesis ... present at the Noble Financial Sixth Annual Equity Conference - ONTRACK ... Hollywood, Florida .  Executive Chairman Paul J. McCormick will ... at 5:00 pm Eastern Time ( 2:00 pm ...
Cached Medicine Technology:Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 2Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 3Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Hospital is the only pediatric hospital in the ... The American Nurses,Credentialing Center (ANCC) has awarded DMC ... nursing. Recognized as one of the,highest distinctions a ... five,percent of all U.S. hospitals have achieved this ...
... April 17 The Connecticut,Hospice, Inc., the nation,s ... from its first class of The Norma F. ... by a,generous grant merited by the Connecticut Hospice,s ... for education and,training in hospice and palliative care. ...
... explain antidepressants, effectiveness , , THURSDAY, April 17 (HealthDay News) ... old brain cells to their more plastic youthful condition ... only provides a possible new explanation for the antidepressant ... prospect that it could be used to treat other ...
... drinkers and heavy,smokers develop Alzheimer,s disease years earlier ... smoke heavily, according to research that,will be presented ... Meeting in Chicago, April 12-19, 2008., "These ... we can,reduce or eliminate heavy smoking and drinking, ...
... N.Y., April 17 CTG (Nasdaq: CTGX ),an ... that it would release its 2008 first quarter,financial results ... company,will hold a conference call to discuss its financial ... 10:00 a.m. Eastern Time. CTG,Chairman and Chief Executive Officer ...
... Calif., April 17 The National Center for,Autism ... for autism research, education and family support,services has ... are,flocking to NCARE resulting from the announcement to ... that families desperately need centralized,autism resources., Soonhee ...
Cached Medicine News:Health News:Children's Hospital of Michigan Awarded Prestigious Magnet Status 2Health News:The Norma F. Pfriem International Fellowship in Hospice and Palliative Care Nursing 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:Alzheimer's Starts Earlier for Heavy Drinkers, Smokers 2Health News:CTG Announces 2008 First Quarter Conference Call and Webcast Information 2Health News:California's First Non-profit Center for Autism Research, Education and Family Services 2
Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Shafts angled 45 degrees, 10 mm from tip to bend. Tips curved with 0.5 mm, 1 x 2 teeth. Serrated handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. Cross action curved shafts. Tip to Angle Length: 12.0 mm. Round handle....
Medicine Products: